Description
Palovarotene, also known as RO-3300074 and R-667, is a highly selective retinoic acid receptor gamma (RAR-gamma) agonist that is under investigation as a potential treatment for emphysema. Phase I clinical trials of palovarotene in patients with emphysema demonstrated that the drug is well tolerated, with improvements observed in markers of emphysema progression. Emphysema is characterized by the destruction of alveoli and alveolar ducts within the lungs. Retinoid signaling is believed to play a role in alveologenesis, with the retinoic acid receptor gamma thought to be required for alveolar formation